Hormonal
There is no consistent causal evidence that higher BMI or Type 2 Diabetes causes changes in chronotype or sleep duration, nor that chronotype or sleep duration causally affect BMI or Type 2 Diabetes, despite observed genetic correlations.
While poor sleep and obesity are linked, this study suggests that one does not necessarily cause the other. You may need to address both sleep hygiene and metabolic health independently, as they might share common genetic roots rather than a direct cause-and-effect relationship.
Mendelian Randomisation analyses, with limited power, provided no consistent evidence of causal associations between BMI or type 2 diabetes and chronotype or sleep duration.
Why this rating
Large sample size (UK Biobank) and robust statistical method (Mendelian Randomization), though the authors note 'limited power' due to the small effect sizes of the genetic instruments.
Source
Genome-Wide Association Analyses in 128,266 Individuals Identifies New Morningness and Sleep Duration Loci
Samuel E. Jones et al. · PLoS Genetics · 2016
DOI 10.1371/journal.pgen.1006125
More from this paper
- Genetic variants associated with morningness (chronotype) and sleep duration are located near genes regulating circadian rhythms (RGS16, PER2) and photoreception (INADL, HTR6), indicating a biological basis for individual differences in sleep timing.Strong
- Genetic variants near the VRK2 gene are associated with shorter sleep duration, with each allele associated with approximately 1.6 to 2.0 minutes less sleep.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →